C

CureVac

Germany - Tübingen
Biotechnology
WebsiteLinkedInCareers Page

Focus: MRNA treatments

CureVac is a life sciences company focused on MRNA treatments.

Gene Therapy
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

CV8102
Rabies
Phase 1
Clinical Trials (1)
NCT02238756Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults
Phase 1
CV2CoV
COVID-19
Phase 1
Clinical Trials (1)
NCT05260437Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
Phase 1
GSK4382276A Dose level 1
Influenza, Human
Phase 1
Clinical Trials (1)
NCT05446740A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
Phase 1
CV7201 mRNA
Rabies
Phase 1
Clinical Trials (1)
NCT02241135RNActive® Rabies Vaccine (CV7201) in Healthy Adults
Phase 1
Phase 1
Clinical Trials (1)
NCT04449276A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
Phase 1
Phase 1
Clinical Trials (1)
NCT01915524Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)
Phase 1
CVSQIV
Influenza
Phase 1
Clinical Trials (1)
NCT05252338A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults
Phase 1
CV09070101 mRNA vaccine
Squamous NSCLC
Phase 1
Clinical Trials (1)
NCT07073183Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)
Phase 1
Phase 1
Clinical Trials (1)
NCT03291002Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
Phase 1
Rabipur®
Rabies
Phase 1
Clinical Trials (1)
NCT03713086A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults
Phase 1
CV09050101 mRNA vaccine
Glioblastoma
Phase 1
Clinical Trials (1)
NCT05938387Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
Phase 1
Phase 1/2
Clinical Trials (1)
NCT01817738Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer
Phase 1/2
F2C22C/DL001Z
Influenza, Human
Phase 1/2
Clinical Trials (1)
NCT05823974A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
Phase 1/2
IMA970A plus CV8102 and Cyclophosphamide
Hepatocellular Carcinoma
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT00923312Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT00906243RNActive®-Derived Therapeutic Vaccine
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT00831467Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease
Phase 1/2
Phase 1/2
CVnCoV 6 μg
Coronavirus
Phase 2
Clinical Trials (1)
NCT04515147A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
Phase 2
Phase 2
Clinical Trials (1)
NCT02140138An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer
Phase 2
CV0701 mRNA COVID-19 Vaccine
SARS-CoV-2
Phase 2
Clinical Trials (1)
NCT05960097A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
Phase 2
CVnCoV
Covid19
Phase 2/3
Clinical Trials (1)
NCT04652102A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
Phase 2/3
SARS-CoV-2 mRNA Vaccine
SARS-CoV-2 Infection
Phase 3
CVnCoV Vaccine
Coronavirus
Phase 3
Clinical Trials (1)
NCT04674189A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19
Phase 3
CVnCoV Vaccine
Coronavirus
Phase 3
Clinical Trials (1)
NCT04860258COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities
Phase 3
CVnCoV Vaccine
Coronavirus
Phase 3
Clinical Trials (1)
NCT04838847A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 23 clinical trials

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles